{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:26Z","timestamp":1790878346704,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Science Foundation Ireland, Strategic Research Cluster Award","award":["08\/SRC\/B1410"],"award-info":[{"award-number":["08\/SRC\/B1410"]}]},{"name":"Molecular Therapeutics for Cancer Ireland (MTCI)"},{"name":"BREAST-PREDICT (CCRC13GAL) program of the Irish Cancer Society"},{"name":"Clinical Cancer Research Trust"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejca.2017.06.023","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T22:30:22Z","timestamp":1501194622000},"page":"258-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":326,"special_numbering":"C","title":["Mutant p53 as a target for cancer treatment"],"prefix":"10.1016","volume":"83","author":[{"given":"Michael J.","family":"Duffy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8331-1143","authenticated-orcid":false,"given":"Naoise C.","family":"Synnott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Crown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.06.023_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrc3711","article-title":"Unravelling mechanisms of p53-mediated tumour suppression","volume":"14","author":"Bieging","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2017.06.023_bib2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrm4007","article-title":"P53 in survival, death and metabolic health: a lifeguard with a licence to kill","volume":"16","author":"Kruiswijk","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ejca.2017.06.023_bib3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","article-title":"Mutant p53 in cancer: new functions and therapeutic opportunities","volume":"25","author":"Muller","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.06.023_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/msb.2011.20","article-title":"Stimulus-dependent dynamics of p53 in single cells","volume":"7","author":"Batchelor","year":"2011","journal-title":"Mol Syst Biol"},{"key":"10.1016\/j.ejca.2017.06.023_bib5","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.1218351","article-title":"p53 dynamics control cell fate","volume":"336","author":"Purvis","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejca.2017.06.023_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cell.2016.03.025","article-title":"Cell-to-cell variation in p53 dynamics leads to fractional killing","volume":"165","author":"Paek","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2017.06.023_bib7","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1080\/15384101.2016.1241917","article-title":"p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis","volume":"15","author":"Fischer","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejca.2017.06.023_bib8","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1101\/gad.1339905","article-title":"P53 isoforms can regulate p53 transcriptional activity","volume":"19","author":"Bourdon","year":"2005","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.023_bib9","doi-asserted-by":"crossref","first-page":"E969136","DOI":"10.4161\/23723548.2014.969136","article-title":"p53 isoforms change p53 paradigm","volume":"1","author":"Bourdon","year":"2014","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ctrv.2014.10.004","article-title":"p53 as a target for the treatment of cancer","volume":"40","author":"Duffy","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2017.06.023_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1389450114666140106101412","article-title":"Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities","volume":"15","author":"Hong","year":"2014","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ejca.2017.06.023_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","article-title":"The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches","volume":"85","author":"Joerger","year":"2016","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.ejca.2017.06.023_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Cancer Genome Atlas Research Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2017.06.023_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib18","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature13176","article-title":"Identification of genomic alterations in oesophageal squamous cell cancer","volume":"509","author":"Song","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1101\/gad.181685.111","article-title":"Mutant p53 cooperates with ETS2 to promote etoposide resistance","volume":"26","author":"Do","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2017.06.023_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fonc.2015.00289","article-title":"Mutant p53: one, no one, and one hundred thousand","volume":"5","author":"Walerych","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib22","doi-asserted-by":"crossref","first-page":"14844","DOI":"10.1038\/ncomms14844","article-title":"Inhibiting the system xC-\/glutathione axis selectively targets cancers with mutant-p53 accumulation","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2017.06.023_bib23","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1101\/gad.263202.115","article-title":"Mutant p53 cooperates with the SWI\/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells","volume":"29","author":"Pfister","year":"2015","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2017.06.023_bib24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature15251","article-title":"Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth","volume":"525","author":"Zhu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib26","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2009.11.026","article-title":"Mutant p53 drives invasion by promoting integrin recycling","volume":"139","author":"Muller","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2017.06.023_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cell.2014.01.066","article-title":"Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor \u03b2 signalling","volume":"157","author":"Weissmueller","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2017.06.023_bib28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ncb3380","article-title":"Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer","volume":"18","author":"Walerych","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ejca.2017.06.023_bib29","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","article-title":"Modeling the therapeutic efficacy of p53 restoration in tumors","volume":"127","author":"Martins","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2017.06.023_bib30","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature05529","article-title":"Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas","volume":"445","author":"Xue","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05541","article-title":"Restoration of p53 function leads to tumour regression in\u00a0vivo","volume":"445","author":"Ventura","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib32","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature09535","article-title":"Stage-specific sensitivity to p53 restoration during lung cancer progression","volume":"468","author":"Feldser","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2017.06.023_bib33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1128\/MCB.00747-15","article-title":"p53 restoration in induction and maintenance of senescence: differential effects in premalignant and malignant tumor cells","volume":"36","author":"Harajly","year":"2015","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2017.06.023_bib34","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1172\/JCI44504","article-title":"Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation","volume":"121","author":"Wang","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2017.06.023_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/bjc.2016.384","article-title":"The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy","volume":"116","author":"Napoli","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2017.06.023_bib36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2017.06.023_bib37","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1038\/sj.onc.1208419","article-title":"PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis","volume":"24","author":"Bykov","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2017.06.023_bib38","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/carcin\/23.12.2011","article-title":"Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute Database","volume":"23","author":"Bykov","year":"2002","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2017.06.023_bib39","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/carcin\/bgm266","article-title":"In\u00a0vitro and in\u00a0vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249","volume":"29","author":"Shi","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejca.2017.06.023_bib40","first-page":"777","article-title":"Re-activation of the p53 pathway inhibits in\u00a0vivo and in\u00a0vitro growth of hormone-dependent human breast cancer cells","volume":"31","author":"Liang","year":"2007","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib41","first-page":"1015","article-title":"PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein","volume":"35","author":"Liang","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10549-010-0851-x","article-title":"Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors","volume":"125","author":"Liang","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2017.06.023_bib43","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-10-3168","article-title":"PRIMA-1Met\/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53","volume":"17","author":"Zandi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.06.023_bib44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ijc.30425","article-title":"Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?","volume":"140","author":"Synnott","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2017.06.023_bib45","first-page":"411","article-title":"PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53","volume":"30","author":"Zache","year":"2008","journal-title":"Cell Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib46","doi-asserted-by":"crossref","first-page":"36689","DOI":"10.18632\/oncotarget.5385","article-title":"PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2017.06.023_bib47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2015.12.002","article-title":"p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E\/K)BRAF melanoma to vemurafenib","volume":"55","author":"Krayem","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.06.023_bib48","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ccr.2009.03.003","article-title":"PRIMA-1 reactivates mutant p53 by covalent binding to the core domain","volume":"15","author":"Lambert","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.06.023_bib49","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/ncomms2361","article-title":"Computational identification of a transiently open L1\/S3 pocket for reactivation of mutant p53","volume":"4","author":"Wassman","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2017.06.023_bib50","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1158\/1535-7163.MCT-12-1166","article-title":"PRIMA-1Met\/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa","volume":"12","author":"Saha","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.023_bib51","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/15384047.2015.1026482","article-title":"PRIMA-1Met induces apoptosis in Waldenstr\u00f6m's macroglobulinemia cells independent of p53","volume":"16","author":"Sobhani","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejca.2017.06.023_bib52","doi-asserted-by":"crossref","first-page":"6442","DOI":"10.1038\/onc.2010.382","article-title":"PRIMA-1(MET)\/APR-246 targets mutant forms of p53 family members p63 and p73","volume":"29","author":"R\u00f6kaeus","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2017.06.023_bib53","doi-asserted-by":"crossref","first-page":"61806","DOI":"10.18632\/oncotarget.11241","article-title":"PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation","volume":"7","author":"Teoh","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2017.06.023_bib54","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.06.023_bib55","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1038\/cddis.2013.417","article-title":"APR-246\/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase","volume":"4","author":"Peng","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejca.2017.06.023_bib56","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.14036","article-title":"Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2\/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells","volume":"174","author":"Ali","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2017.06.023_bib57","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3892\/or.2016.4653","article-title":"PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells","volume":"35","author":"Yoshikawa","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2017.06.023_bib58","doi-asserted-by":"crossref","first-page":"e1794","DOI":"10.1038\/cddis.2015.143","article-title":"APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells","volume":"6","author":"Mohell","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ejca.2017.06.023_bib59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.canlet.2016.03.017","article-title":"APR-246 (PRIMA-1MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines","volume":"375","author":"Deben","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2017.06.023_bib60","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10637-014-0090-9","article-title":"PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines","volume":"32","author":"Izetti","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2017.06.023_bib61","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/gutjnl-2015-309770","article-title":"APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.ejca.2017.06.023_bib62","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2010.01557.x","article-title":"APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells","volume":"86","author":"Ali","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejca.2017.06.023_bib63","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2011.40.7783","article-title":"Targeting p53 in\u00a0vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer","volume":"30","author":"Lehmann","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.5571","article-title":"A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC)","volume":"34","author":"Gourley","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib65","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps5605","article-title":"EUTROC PiSARRO: a phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC)","volume":"33","author":"Gourley","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib66","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1093\/nar\/gkt305","article-title":"Small molecule induced reactivation of mutant p53 in cancer cells","volume":"41","author":"Liu","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ejca.2017.06.023_bib67","doi-asserted-by":"crossref","first-page":"E5271","DOI":"10.1073\/pnas.1610421113","article-title":"2-Sulfonylpyrimidines: mild alkylating agents with anticancer activity toward p53-compromised cells","volume":"113","author":"Bauer","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl; abstr e14099","key":"10.1016\/j.ejca.2017.06.023_bib68","article-title":"Targeting mutant p53 with PK11007: a new approach for the treatment of patients with triple-negative breast cancer?","volume":"35","author":"Synnott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.06.023_bib69","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1124\/mol.114.097550","article-title":"Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore","volume":"87","author":"Blanden","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ejca.2017.06.023_bib70","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ccr.2012.03.042","article-title":"Allele-specific p53 mutant reactivation","volume":"21","author":"Yu","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.06.023_bib71","doi-asserted-by":"crossref","first-page":"8879","DOI":"10.18632\/oncotarget.2432","article-title":"Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism","volume":"5","author":"Yu","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2017.06.023_bib72","doi-asserted-by":"crossref","first-page":"41363","DOI":"10.18632\/oncotarget.9133","article-title":"COTI-2, a novel small molecule that is active against multiple human cancer cell lines in\u00a0vitro and in\u00a0vivo","volume":"7","author":"Salim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2017.06.023_bib73","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(16)32638-7","article-title":"COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K\/AKT\/mTOR pathway","volume":"69","author":"Salim","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.06.023_bib74","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm0697-632","article-title":"Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain","volume":"3","author":"Selivanova","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2017.06.023_bib75","doi-asserted-by":"crossref","first-page":"11817","DOI":"10.18632\/oncotarget.7857","article-title":"Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides","volume":"7","author":"Tal","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2017.06.023_bib76","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1073\/pnas.241629998","article-title":"A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants","volume":"99","author":"Friedler","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2017.06.023_bib77","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ccell.2015.12.002","article-title":"A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas","volume":"29","author":"Soragni","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2017.06.023_bib78","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1080\/13543776.2017.1233179","article-title":"Peptides and peptidomimetics in the p53\/MDM2\/MDM4 circuitry \u2013 a patent review","volume":"26","author":"Teveroni","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.ejca.2017.06.023_bib79","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","article-title":"Peptide therapeutics: current status and future directions","volume":"20","author":"Fosgerau","year":"2015","journal-title":"Drug Discov Today"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917310742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917310742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T14:33:50Z","timestamp":1602599630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917310742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":79,"alternative-id":["S0959804917310742"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.06.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutant p53 as a target for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}